Orbimed Advisors LLC Reduces Stake in Eli Lilly and Company $LLY

Orbimed Advisors LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 21.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 236,800 shares of the company’s stock after selling 64,400 shares during the quarter. Eli Lilly and Company comprises about 4.0% of Orbimed Advisors LLC’s portfolio, making the stock its 6th largest holding. Orbimed Advisors LLC’s holdings in Eli Lilly and Company were worth $217,802,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Cardiff Park Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.7% during the first quarter. Cardiff Park Advisors LLC now owns 835 shares of the company’s stock worth $768,000 after purchasing an additional 14 shares during the period. Gateway Wealth Partners LLC boosted its stake in Eli Lilly and Company by 279.8% in the 1st quarter. Gateway Wealth Partners LLC now owns 4,087 shares of the company’s stock valued at $3,759,000 after purchasing an additional 3,011 shares during the period. Wealth Watch Advisors INC grew its holdings in Eli Lilly and Company by 8.7% in the 1st quarter. Wealth Watch Advisors INC now owns 426 shares of the company’s stock valued at $392,000 after buying an additional 34 shares in the last quarter. Blue Chip Partners LLC grew its holdings in Eli Lilly and Company by 0.7% in the 1st quarter. Blue Chip Partners LLC now owns 35,447 shares of the company’s stock valued at $32,603,000 after buying an additional 262 shares in the last quarter. Finally, Weiss Asset Management LP increased its position in Eli Lilly and Company by 734.2% during the 1st quarter. Weiss Asset Management LP now owns 3,070 shares of the company’s stock worth $2,824,000 after buying an additional 2,702 shares during the period. Institutional investors own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly reported strong late-stage results for retatrutide, its next-generation obesity drug, in two Phase 3 trials. The drug met its primary endpoint and produced substantial weight loss and A1C improvement, reinforcing expectations for a major future growth franchise. Article Title
• Positive Sentiment: The company said it now plans to file for FDA approval of retatrutide in Q1 2027, keeping the drug on a path toward commercialization and supporting the long-term growth outlook for LLY. Article Title
• Positive Sentiment: A Lilly-backed biotech, Scribe Therapeutics, priced an upsized IPO with strong demand, highlighting continued investor appetite for Lilly-associated pipeline assets and partnerships. Article Title
• Neutral Sentiment: Healthcare stocks were broadly higher late Friday, which may be lending general support to Eli Lilly’s shares. Article Title
• Negative Sentiment: Novo Nordisk is seeking a preliminary injunction to block Lilly’s weight-loss and diabetes ads, accusing the company of using outdated data and misleading comparisons versus Wegovy and Ozempic. That raises legal and regulatory risk for Eli Lilly, even if the impact is likely more headline-driven than fundamental for now. Article Title

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,196.18 on Monday. The stock has a fifty day moving average price of $1,136.56 and a 200-day moving average price of $1,040.14. The company has a market cap of $1.13 trillion, a price-to-earnings ratio of 42.49, a PEG ratio of 1.48 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.03 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Rothschild & Co Redburn lifted their target price on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.